Netherlands-based ViCentra, a medical device firm innovating in insulin delivery for people with diabetes, announced the successful close of an upsized $85 million Series D financing.
The round was led by new investor Innovation Industries, a leading European deeptech venture capital firm, with matching participation from existing investors Partners in Equity and Invest-NL, alongside continued support from EQT Life Sciences and Health Innovations.
“With this fresh funding, ViCentra will accelerate manufacturing scale-up, launch the next-generation Kaleido 2 patch pump in Europe, and prepare for U.S. market entry,” said ViCentra.
“Kaleido is the smallest, lightest, and most precise insulin patch pump in its class, uniquely designed as a lifestyle product that is discreet, intuitive, and personalized.
“Designed to feel more like personal technology than a traditional medical device, Kaleido features premium materials, and users can select their own favorite aluminum shells from a range of ten preset color options.
“Integrated with Diabeloop’s self-learning automated insulin delivery algorithm and compatible with the Dexcom CGM sensor, Kaleido positions ViCentra at the forefront of next-generation diabetes care, helping reach many more users and improve the quality of life for people with diabetes.
“Strong initial commercial uptake of Kaleido in Germany, France, and the Netherlands has driven demand beyond initial expectations. This financing enables ViCentra to scale the business for rapid revenue acceleration.”
ViCentra CEO Tom Arnold said: “Kaleido is a true disruptor — small, discreet, featherlight, and beautifully designed. It empowers people with diabetes by offering a more personal and distinctive choice in both function and style.
“Built with empathy and precision, it honors those who live with diabetes every day. With this funding, we can now meet surging European demand and fast-track our entry into the U.S. market. This is a pivotal moment — for ViCentra, and for the community we serve.”
Caaj Greebe, Partner at Innovation Industries, said: “ViCentra is redefining insulin pump therapy with a platform that truly centers the user experience – combining clinical performance with design simplicity and wearability.
“At Innovation Industries, we invest in pioneering companies that blend world-class technology with clear commercial potential. ViCentra exemplifies this by delivering a next-generation system addressing the urgent need for better treatment options in diabetes care.
“We’re proud to lead this investment round and partner with Tom and the team as they deepen and expand their presence in Europe and prepare for U.S. entry.”